This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 ...
Amgen bought Synergen after its interleukin-1 antagonist, Antril, failed clinical trials in July 1994 and the company was forced to hold a fire sale of its facilities, intellectual property ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback